TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7776528

Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg.kg‐1 + bupivacaine 5 ml
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg.kg‐1 + bupivacaine 5 ml
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg.kg‐1 + bupivacaine 5 ml
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.25% bupivacaine 5 ml only
Number of subjects: 24
Study: 2109992

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonazepam (CZP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple-drug therapy
Number of subjects: 0
Study: 508509

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate immediately before breakfast (EB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate immediately after breakfast (EA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythromycin base immediately before breakfast (eB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythromycin base immediately after breakfast (eA)
Number of subjects: 16
Study: 31524779

Group type: EXPERIMENTAL
Intervention: High-resistance circuit training in hypoxia (HG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-resistance circuit training in normoxia (NG)
Number of subjects: 28
Study: 31489467

Group type: EXPERIMENTAL
Intervention: Dried beancurd (100 g/day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Rice cake (control group, 100 g/day)
Number of subjects: 300
Study: 30417894

Group type: EXPERIMENTAL
Intervention: One injection of pressed ceramic
Number of subjects: 48

Group type: COMPARATOR
Intervention: Two injections of pressed ceramic
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Three injections of pressed ceramic
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: One injection of pressed ceramic (aged)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Two injections of pressed ceramic (aged)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Three injections of pressed ceramic (aged)
Number of subjects: 48
Study: 26770983

Group type: EXPERIMENTAL
Intervention: Acarbose (150 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (no acarbose)
Number of subjects: 135
Study: 24594561

Group type: EXPERIMENTAL
Intervention: Automated telephone self-management support/health coaching intervention for 27 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 22314263

Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DMQ) 45/30 mg
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DMQ) 30/30 mg
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 20870984

Group type: EXPERIMENTAL
Intervention: Heated humidification (HH)
Number of subjects: 2833

Group type: COMPARATOR
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 2833
Study: 17585081

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia at 33 degrees C for 24 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 70
Study: 16100176

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care management (control)
Number of subjects: 84
Study: 12071936

Group type: EXPERIMENTAL
Intervention: ATG/ALG
Number of subjects: 10
Study: 10522855

Group type: EXPERIMENTAL
Intervention: Conservative approach with close monitoring and selective intervention (TAE or surgical intervention)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Aggressive approach with surgical intervention or attempted transarterial embolization (TAE)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Excluding 36 patients with end-stage malignant neoplasms
Number of subjects: 112
Study: 7742436

Group type: EXPERIMENTAL
Intervention: Two doses of Oka/Merck varicella vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: One dose of Oka/Merck varicella vaccine
Number of subjects: 0
Study: 2139442

Group type: EXPERIMENTAL
Intervention: Aspirin (324 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Preoperative beta-thromboglobulin levels
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 105
Study: 7302777

Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 0
Study: 29514801

Group type: EXPERIMENTAL
Intervention: Intramuscular glucocorticoid injection (40 mg triamcinolone acetate)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 107
Study: 26509817

Group type: EXPERIMENTAL
Intervention: 30 mg/kg IV methylprednisolone (neonate trial)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 30 mg/kg IV methylprednisolone after anesthesia induction (ventricular septal defect trial)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 30 mg/kg methylprednisolone in the cardiopulmonary bypass prime solution (ventricular septal defect trial)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (neonate trial)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (ventricular septal defect trial)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 30 mg/kg IV methylprednisolone (ventricular septal defect trial)
Number of subjects: 85
Study: 24447620

Group type: EXPERIMENTAL
Intervention: Olesoxime (330 mg daily)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 22421303

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Cutting balloon angioplasty
Number of subjects: 162

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 162
Study: 19965659

Group type: EXPERIMENTAL
Intervention: MEL200 (200 mg/m²)
Number of subjects: 298

Group type: COMPARATOR
Intervention: MEL100 (100 mg/m²)
Number of subjects: 298
Study: 18206857

Group type: EXPERIMENTAL
Intervention: 18 mg/day prolonged-release methylphenidate
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: 36 mg/day prolonged-release methylphenidate
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: 72 mg/day prolonged-release methylphenidate
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 16816797

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotic (perphenazine)
Number of subjects: 0
Study: 12640371

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 30
Study: 10845350

Group type: EXPERIMENTAL
Intervention: Preparation group (videotape shown the evening before surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 8805113

Group type: EXPERIMENTAL
Intervention: 10% peppermint oil in ethanol solution
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 500 mg acetaminophen
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (90% ethanol solution with traces of peppermint oil)
Number of subjects: 41
Study: 1610539

Group type: COMPARATOR
Intervention: Cholestyramine (24 g daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lovastatin (80 mg daily)
Number of subjects: 120
Study: 6428899

Group type: EXPERIMENTAL
Intervention: Infusion of hydroxy‐ethyl‐starch cryopreserved blood with free haemoglobin
Number of subjects: 5
Study: 31871348

Group type: EXPERIMENTAL
Intervention: Rewatching recorded lecture
Number of subjects: 102

Group type: COMPARATOR
Intervention: Retrieval practice
Number of subjects: 102
Study: 31016010

Group type: EXPERIMENTAL
Intervention: PEERS social skills intervention program
Number of subjects: 6
Study: 24726684

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to participants with MTSS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to healthy participants
Number of subjects: 40
Study: 24113902

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) program
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 193
Study: 22325125

Group type: EXPERIMENTAL
Intervention: Higher retaliatory attitudes at baseline
Number of subjects: 129

Group type: COMPARATOR
Intervention: Retaliatory attitudes assessment
Number of subjects: 129
Study: 20447535

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4513

Group type: EXPERIMENTAL
Intervention: Low-level increases in cTnI (0.04 microg/l to <0.1 microg/l)
Number of subjects: 4513
Study: 18067658

Group type: EXPERIMENTAL
Intervention: Hip strengthening exercises (6 exercises for hip abductor and adductor muscles, 5 times per week for 12 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 88
Study: 16225575

Group type: EXPERIMENTAL
Intervention: hCG treatment
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 183
Study: 12405574

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional therapy only (group B)
Number of subjects: 57
Study: 10208245

Group type: EXPERIMENTAL
Intervention: 1-h muscle strength training session of the upper extremities
Number of subjects: 30

Group type: COMPARATOR
Intervention: Motor performance tests (no intervention)
Number of subjects: 30
Study: 8526759

Group type: EXPERIMENTAL
Intervention: Chronic heart failure stage II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without heart failure
Number of subjects: 0
Study: 2223429

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 798190

Group type: EXPERIMENTAL
Intervention: Higher than usual dosages of haloperidol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 38
Study: 31977882

Group type: EXPERIMENTAL
Intervention: Supervised early exercise program in combination with standard treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 118
Study: 26179181

Group type: EXPERIMENTAL
Intervention: Citicoline (250 or 500 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29077149

Group type: EXPERIMENTAL
Intervention: dl-3-n-Butylphthalide (NBP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine drug therapy (Control)
Number of subjects: 160
Study: 25376719

Group type: EXPERIMENTAL
Intervention: Active hexose correlated compound (1.0 g/d for 4 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23778476

Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin/1% prednisolone acetate fixed combination eye drops
Number of subjects: 108

Group type: COMPARATOR
Intervention: 0.3% gatifloxacin and 1% prednisolone acetate eye drops separately (control)
Number of subjects: 108
Study: 16717081

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Anaemic patients
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Patients without anaemia at baseline
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Patients with Hb decrease of >3 g/dL
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Patients with Hb decrease of 2.0-3.0 g/dL
Number of subjects: 3029
Study: 15259286

Group type: EXPERIMENTAL
Intervention: Oral continuous combined E2 1 mg and NETA 0.25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral continuous combined E2 1 mg and NETA 0.5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 10910801

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8932834

Group type: EXPERIMENTAL
Intervention: Blood cell and bone marrow transplants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood, bone marrow and cord blood cell transplants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graft‐versus‐host disease
Number of subjects: 0
Study: 1558269

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 0
Study: 3901389

Group type: EXPERIMENTAL
Intervention: Org OD14 (2.5 mg daily for 12 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31675674

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Resistance training combined with nutritional supplement (RTS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 117
Study: 30831295

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 82

Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 82
Study: 27769543

Group type: EXPERIMENTAL
Intervention: Short course of potassium iodide (SSKI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No potassium iodide (control group)
Number of subjects: 0
Study: 25600515

Group type: EXPERIMENTAL
Intervention: Individual Interpersonal Psychotherapy (IPT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT)
Number of subjects: 39
Study: 22079383

Group type: EXPERIMENTAL
Intervention: SAFETY Intervention (SI) - home-based assessment, extensive clinical profiling, optimal pharmacology tailored to clinical stability and risk profile
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual post-discharge care
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: SAFETY Intervention (SI)
Number of subjects: 320
Study: 22036605

Group type: EXPERIMENTAL
Intervention: Intranasal hypocretin-1 (orexin A) (435 nmol)
Number of subjects: 8
Study: 19644228

Group type: EXPERIMENTAL
Intervention: Fast-titration group (4 mg/24 h starting dose, increasing by 4 mg/24 h per week to a maximum of 24 mg/24 h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Slow-titration group (4 mg/24 h starting dose, increasing by 2 mg/24 h per week to a maximum of 24 mg/24 h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (combined results)
Number of subjects: 34
Study: 17378819

Group type: EXPERIMENTAL
Intervention: Issuing early results from a rapid molecular test for chromosomal abnormalities
Number of subjects: 226

Group type: COMPARATOR
Intervention: Issuing karyotype results on a fixed date
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Receiving rapid test results
Number of subjects: 226

Group type: COMPARATOR
Intervention: Receiving only full karyotype results
Number of subjects: 226
Study: 15650420

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 112
Study: 11465621

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.0 MAC
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.8 MAC
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.8 MAC
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 64
Study: 9554186

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Career decided group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Career undecided group
Number of subjects: 0
Study: 7992149

Group type: EXPERIMENTAL
Intervention: Laparoscopic Toupet partial fundoplication
Number of subjects: 28

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 28
Study: 2660250

Group type: EXPERIMENTAL
Intervention: Propranolol, 160 mg daily for 6 months (n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 31
Study: 31897524

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg once weekly
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: canagliflozin 300 mg once daily
Number of subjects: 178
Study: 30924902

Group type: EXPERIMENTAL
Intervention: Higher incentives with both parent and child required to meet the goal
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Gain-framed payment structure
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Incentivizing physical activity goals
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Incentivizing dietary monitoring
Number of subjects: 339

Group type: COMPARATOR
Intervention: Lottery for a large incentive
Number of subjects: 339
Study: 28838145

Group type: EXPERIMENTAL
Intervention: Valganciclovir
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 26346836

Group type: EXPERIMENTAL
Intervention: Errorless Goal Management Training (EL-GMT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional Goal Management Training (GMT)
Number of subjects: 67
Study: 23735647

Group type: EXPERIMENTAL
Intervention: Plasma vitamin D-binding protein (VDBP) levels
Number of subjects: 928

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 928
Study: 22132950

Group type: EXPERIMENTAL
Intervention: Febuxostat (approved doses)
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Allopurinol (commonly prescribed doses)
Number of subjects: 2268
Study: 19638331

Group type: EXPERIMENTAL
Intervention: L2 spinal nerve block (n = 30), 1.5 mL of 1% lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcutaneous injection (control, n = 30), 1.5 mL of 1% lidocaine
Number of subjects: 60
Study: 17129516

Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (t-PA)
Number of subjects: 53
Study: 15005346

Group type: EXPERIMENTAL
Intervention: MCNU-COP/MP
Number of subjects: 210

Group type: COMPARATOR
Intervention: mCOP/MP
Number of subjects: 210
Study: 11188774

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment at a dose of 400 mg/kg bodyweight every 4 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 9277437

Group type: EXPERIMENTAL
Intervention: Infusion of nutrients (protein, fat, carbohydrate) at 40, 90, and 160 kcal/h into the duodenum
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Infusion of more calories into the duodenum
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Greater amounts and concentrations of calories and carbohydrate during jejunoileal transit
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Delivery of bile acids and chymotrypsin to the distal jejunum
Number of subjects: 26
Study: 8339523

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil 1000 mg/m2 and cis-platinum 20 mg/m2 for 5 consecutive days, with retinol palmitate at 15,000 IU b.i.d. in chemotherapy intervals
Number of subjects: 23
Study: 3089050

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (20 ml)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Diamorphine 2.5 mg in 10 ml normal saline
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 29122370

Group type: EXPERIMENTAL
Intervention: Graded motor imagery (GMI) in addition to traditional rehabilitation for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group received traditional rehabilitation for 8 weeks
Number of subjects: 36
Study: 24886638

Group type: EXPERIMENTAL
Intervention: Hatha yoga exercise program (8-week duration, group and home-based sessions)
Number of subjects: 36
Study: 22270380

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance with dietary intervention for 6 months
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pooled subjects (N=218)
Number of subjects: 125
Study: 20604937

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 18354383

Group type: EXPERIMENTAL
Intervention: Benazepril with hydrochlorothiazide
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Benazepril with amlodipine
Number of subjects: 332

Group type: COMPARATOR
Intervention: ACE inhibitor and calcium channel blocker
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: ACE inhibitor and thiazide diuretic
Number of subjects: 332
Study: 16061709

Group type: EXPERIMENTAL
Intervention: Pathogen directed treatment (PDT)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Empirical broad spectrum antibiotic treatment (EAT)
Number of subjects: 262
Study: 11919230

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens including bolus fluorouracil (5‐FU), 5‐FU and leucovorin, 5‐FU and levamisole, and 5‐FU, leucovorin, and levamisole followed by chemoradiation therapy (pelvic irradiation at 45 Gy with a boost to 50.4 to 54 Gy)
Number of subjects: 1695
Study: 10652116

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg (Imigran 0.5 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8888372

Group type: EXPERIMENTAL
Intervention: CDP-choline (single oral dose)
Number of subjects: 0
Study: 1667392

Group type: EXPERIMENTAL
Intervention: Long-term intake of ispaghula (6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wheat fibers (6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active phase of total colitis
Number of subjects: 0
Study: 6289096

Group type: EXPERIMENTAL
Intervention: Cerebral gangliosides (50 mg once a day) for 40 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 30719926

Group type: EXPERIMENTAL
Intervention: Semi-inclusive room layout
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Inclusive room layout
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Exclusive room layout
Number of subjects: 362
Study: 28870140

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 3661

Group type: COMPARATOR
Intervention: TIV-Victoria (Vic)
Number of subjects: 3661

Group type: COMPARATOR
Intervention: TIV-Yamagata (Yam)
Number of subjects: 3661